Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Ask Hep looks at drugs and supplements that may interact with direct-acting antivirals used to treat hepatitis C.
This finding from a study of people with both diseases underlines the importance of treating the virus.
Curing hep C slashes risk of death for those with liver cancer history
Ask Hep explains why people who are starting treatment for hepatitis C, should be tested for hepatitis B.
Sustained response to direct-acting antivirals prolonged survival by a year and a half.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
Do you wonder if the medicines and other substances you take interact with each other? For more about this, read Ask Hep.
Large European study finds that more than 1 in 10 people with HIV acquire HCV again.
The argument has always been that the risk of damage from ribavirin’s toxicity is offset by its antiviral qualities.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
A look at the risks and rewards of hepatitis C treatment.
A meta-analysis has helped clear up conflicting previous evidence regarding this association.
University of Washington School of Medicine specialist comments on study findings published in JAMA Network Open.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
The VA has cured HCV in nearly 100,000 veterans, which will dramatically reduce the development of advanced liver disease and liver cancer.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.